SCHEMBL26412504

SCHEMBL26412504

CCCN1CCC(NC(C)C)CC1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PABPC1 P11940 1/20 0.44
EPHX1 P07099 1/20 0.41
EPHX2 P34913 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
DRD2 P14416 3/20 0.41
ROCK2 O75116 1/20 0.40
ROCK1 Q13464 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
GNAI3 P08754 1/20 0.39
GNAO1 P09471 1/20 0.39
GNAI1 P63096 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.37
UBE2M P61081 1/20 0.36
DCUN1D1 Q96GG9 1/20 0.36
PKM P14618 1/20 0.36
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25579282 0.89 DRD2 (0.39) PABPC1EPHX1EPHX2L3MBTL1DRD2
SCHEMBL2621577 0.83 KDM4E (0.40) EPHX1EPHX2MEN1KMT2ASMN1; SMN2
SCHEMBL24607256 0.83 CYP2D6 (0.36) PABPC1EPHX1EPHX2L3MBTL1DRD2
SCHEMBL12536296 0.82 HTR4 (0.38) DRD2ROCK2ROCK1GNAI3GNAO1
SCHEMBL25568027 0.82 ROCK2 (0.37) ROCK2ROCK1
SCHEMBL2621571 0.82 KMT2A (0.47) EPHX2MEN1KMT2ASMN1; SMN2PKM
SCHEMBL25123563 0.81 GNAI3 (0.39) EPHX1EPHX2GNAI3GNAO1GNAI1
SCHEMBL18539746 0.80 CYP2D6 (0.40) PABPC1L3MBTL1GNAI3GNAO1GNAI1
SCHEMBL24848353 0.80 PABPC1 (0.37) PABPC1EPHX1EPHX2L3MBTL1DRD2
SCHEMBL22794388 0.80 GNAI3 (0.41) EPHX1EPHX2GNAI3GNAO1GNAI1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357180-A1 DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2023-11-09 US disclosed
US-20230130516-A1 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS BRISTOL-MYERS SQUIBB COMPANY 2023-04-27 US disclosed
US-20230131192-A1 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS BRISTOL-MYERS SQUIBB COMPANY 2023-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230131192-A1 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS TLR7, TLR9, TLR1 PABPC1 1023/4885EPHX1 2393/4885EPHX2 3766/4885
US-20230130516-A1 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS TLR7, TLR1, TLR9 PABPC1 870/4885EPHX1 2314/4885EPHX2 3750/4885
US-20230357180-A1 DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION STUB1, MDM2, USP30 PABPC1 483/4885EPHX1 4176/4885EPHX2 4104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.